References in periodicals archive ?
In the first penile transplantation,9 pre and intra-operative immunosuppressive induction regimens were administered [50 mg of Zenapax, 1000 mg of mycophenolate mofetil (MMF) at 1.5 h preoperatively, 0.5 g of methylprednisolone intraoperatively, and 0.5 g of methylprednisolone postoperatively on days 1, 2, and 3].
Additionally, daclizumab (Zenapax), which was approved several years ago for prophylaxis of acute organ rejection in patients receiving renal transplants, was approved for multiple sclerosis treatment (Zinbryta) last year, and sofosbuvir (Sovaldi), which was approved in 2013 for the treatment of hepatitis C virus, is now combined with velpatasvir (Epclusa) to treat all six major forms of hepatitis C.
Induction immunosuppression consisted of daclizumab (Zenapax) (weight <40 kg: 10 mg intravenous injection (IVI) on days 1 and 4; weight >40 kg: 20 mg IVI on days 1 and 4) and methylprednisolone (Solu-Medrol) (600 mg/[m.sup.2] to a maximum of 500 mg).
All patients received induction therapy with either Alemtuzumab (Campath 1H), Daclizumab (Zenapax), or a few with glucocorticosteroids.
Drugs in development that target the immune system include rituximab, sold under the brand name Rituxan by Roche and Biogen to fight leukemia, Tysabri from Biogen and Elan , Lemtrada, sold as Campath by Sanofi's unit Genzyme for cancer, and Abbott and Biogen's Zenapax or daclizumab.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Zenapax (daclizumab), which also blocks signaling cytokines, was tested in a placebo-controlled trial of 270 people with active relapsing MS.
We believe this strategic move will permit us to maximize the potential value of Zenapax and Nuvion, as we are building significant competence ahead of our hoped for product introductions in 2007 and beyond.
A laboratory-created monoclonal antibody, Zenapax blocks the activity of a key immune activator in MS.
In an exploratory 12-month study of 55 heart transplant patients, adjunct treatment with the humanized monoclonal antibody Zenapax (daclizumab) reduced the number and severity of early organ rejection episodes, according to researchers at Columbia Presbyterian Center of New York Presbyterian Hospital.
Roche Holding AG, Basel, Switzerland, has been given approval by the European Union (EU) regulators to market Zenapax (daclizumab) for patients who have received kidney transplants.
Patients received induction therapy with rATG (Thymoglobulin, Genzyme) or daclizumab (Zenapax, Roche) in a case of PRA > 50% and 20%, respectively.